Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Extension in Pediatric SBS
NCT02954458Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2017
- Primary completion
- Nov 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 46 months, Change From Baseline in Average Total Urine Output and 9 more. Started Jan 2017; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02954458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954458.